Lauren D Garfield1, David Dixon2, Petra Nowotny2, Francis E Lotrich3, Bruce G Pollock4, Sean D Kristjansson2, Peter M Doré2, Eric J Lenze2. 1. Department of Psychiatry, Washington University School of Medicine, St. Louis, MO. Electronic address: garfiell@psychiatry.wustl.edu. 2. Department of Psychiatry, Washington University School of Medicine, St. Louis, MO. 3. Western Psychiatric Institute and Clinic, University of Pittsburgh, Pittsburgh, PA. 4. Campbell Family Mental Health Research Institute-Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada.
Abstract
OBJECTIVE: Antidepressant side effects are a significant public health issue, associated with poor adherence, premature treatment discontinuation, and, rarely, significant harm. Older adults assume the largest and most serious burden of medication side effects. We investigated the association between antidepressant side effects and genetic variation in the serotonin system in anxious, older adults participating in a randomized, placebo-controlled trial of the selective serotonin reuptake inhibitor (SSRI) escitalopram. METHODS: Adults (N = 177) aged ≥ 60 years were randomized to active treatment or placebo for 12 weeks. Side effects were assessed using the Udvalg fur Kliniske Undersøgelser side-effect rating scale. Genetic polymorphisms were putative functional variants in the promoters of the serotonin transporter and 1A and 2A receptors (5-HTTLPR [L/S + rs25531], HTR1A rs6295, HTR2A rs6311, respectively). RESULTS: Four significant drug-placebo side-effect differences were found: increased duration of sleep, dry mouth, diarrhea, and diminished sexual desire. Analyses using putative high- versus low-transcription genotype groupings revealed six pharmacogenetic effects: greater dry mouth and decreased sexual desire for the low- and high-expressing serotonin transporter genotypes, respectively, and greater diarrhea with the 1A receptor low-transcription genotype. Diminished sexual desire was experienced significantly more by high-expressing genotypes in the serotonin transporter, 1A, or 2A receptors. There was not a significant relationship between drug concentration and side effects nor a mean difference in drug concentration between low- and high-expressing genotypes. CONCLUSION: Genetic variation in the serotonin system may predict who develops common SSRI side effects and why. More work is needed to further characterize this genetic modulation and to translate research findings into strategies useful for more personalized patient care. Published by Elsevier Inc.
RCT Entities:
OBJECTIVE: Antidepressant side effects are a significant public health issue, associated with poor adherence, premature treatment discontinuation, and, rarely, significant harm. Older adults assume the largest and most serious burden of medication side effects. We investigated the association between antidepressant side effects and genetic variation in the serotonin system in anxious, older adults participating in a randomized, placebo-controlled trial of the selective serotonin reuptake inhibitor (SSRI) escitalopram. METHODS: Adults (N = 177) aged ≥ 60 years were randomized to active treatment or placebo for 12 weeks. Side effects were assessed using the Udvalg fur Kliniske Undersøgelser side-effect rating scale. Genetic polymorphisms were putative functional variants in the promoters of the serotonin transporter and 1A and 2A receptors (5-HTTLPR [L/S + rs25531], HTR1Ars6295, HTR2Ars6311, respectively). RESULTS: Four significant drug-placebo side-effect differences were found: increased duration of sleep, dry mouth, diarrhea, and diminished sexual desire. Analyses using putative high- versus low-transcription genotype groupings revealed six pharmacogenetic effects: greater dry mouth and decreased sexual desire for the low- and high-expressing serotonin transporter genotypes, respectively, and greater diarrhea with the 1A receptor low-transcription genotype. Diminished sexual desire was experienced significantly more by high-expressing genotypes in the serotonin transporter, 1A, or 2A receptors. There was not a significant relationship between drug concentration and side effects nor a mean difference in drug concentration between low- and high-expressing genotypes. CONCLUSION: Genetic variation in the serotonin system may predict who develops common SSRI side effects and why. More work is needed to further characterize this genetic modulation and to translate research findings into strategies useful for more personalized patient care. Published by Elsevier Inc.
Entities:
Keywords:
SSRI; older adults; pharmacogenetic; serotonin; side effects
Authors: Tami L Mark; Vijay N Joish; Joel W Hay; David V Sheehan; Stephen S Johnston; Zhun Cao Journal: Am J Geriatr Psychiatry Date: 2011-03 Impact factor: 4.105
Authors: Jin H Joo; Eric J Lenze; Benoit H Mulsant; Amy E Begley; Elizabeth M Weber; Jacqueline A Stack; Sati Mazumdar; Charles F Reynolds; Bruce G Pollock Journal: J Clin Psychiatry Date: 2002-10 Impact factor: 4.384
Authors: Gerald Gartlehner; Richard A Hansen; Timothy S Carey; Kathleen N Lohr; Bradley N Gaynes; Leah C Randolph Journal: Int Clin Psychopharmacol Date: 2005-03 Impact factor: 1.659
Authors: Muhammad Mamdani; Mark Rapoport; Kenneth I Shulman; Nathan Herrmann; Paula A Rochon Journal: Am J Geriatr Psychiatry Date: 2005-10 Impact factor: 4.105
Authors: Yuyan Jin; Bruce G Pollock; Ellen Frank; Jeff Florian; Margaret Kirshner; Andrea Fagiolini; David J Kupfer; Marc R Gastonguay; Gail Kepple; Yan Feng; Robert R Bies Journal: J Clin Pharmacol Date: 2009-02 Impact factor: 3.126
Authors: Eric J Lenze; Bruce L Rollman; M Katherine Shear; Mary Amanda Dew; Bruce G Pollock; Caroline Ciliberti; Michelle Costantino; Sara Snyder; Peichang Shi; Edward Spitznagel; Carmen Andreescu; Meryl A Butters; Charles F Reynolds Journal: JAMA Date: 2009-01-21 Impact factor: 56.272
Authors: Antoine Yrondi; Laura M Fiori; Benicio N Frey; Raymond W Lam; Glenda M MacQueen; Roumen Milev; Daniel J Müller; Jane A Foster; Sidney H Kennedy; Gustavo Turecki Journal: Int J Neuropsychopharmacol Date: 2020-02-01 Impact factor: 5.176